42.96
-2.08(-4.62%)
Currency In USD
| Previous Close | 45.04 |
| Open | 44.06 |
| Day High | 44.7 |
| Day Low | 42.38 |
| 52-Week High | 48.61 |
| 52-Week Low | 13.88 |
| Volume | 2.25M |
| Average Volume | 2.14M |
| Market Cap | 3.99B |
| PE | -85.92 |
| EPS | -0.5 |
| Moving Average 50 Days | 38.57 |
| Moving Average 200 Days | 31.58 |
| Change | -2.08 |
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
GlobeNewswire Inc.
Mar 17, 2025 11:01 AM GMT
sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure Add
Travere Therapeutics to Participate at Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 24, 2025 9:30 PM GMT
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences in March: TD Cowen 45th Annual Health Care ConferencePres
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire Inc.
Feb 13, 2025 9:30 PM GMT
SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial markets.